What is the typical protocol for BPC-157?

250–500 mcg, 1–2× daily, for 4–6 weeks on, 4 weeks off. Route: Subcutaneous or oral (gut-localized). Half-life: ~4 hours (subcutaneous).

What are the side effects and contraindications of BPC-157?

Generally well tolerated in animal studies; Injection site irritation; Long-term human safety unknown Avoid in: Active malignancy (theoretical angiogenic concern), Pregnancy and lactation.

Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions.

Peptides/Regenerative

BPC-157

Grade B

Studied extensively in animal models for tendon, ligament, muscle, and gut mucosal healing. Human evidence is limited to small clinical observations.

Mechanism of Action

Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.

Typical Protocol

Dose

250–500 mcg

Frequency

1–2× daily

Duration

4–6 weeks on, 4 weeks off

Timing

Near site of injury or AM/PM fasted

Route

Subcutaneous or oral (gut-localized)

Half-life

~4 hours (subcutaneous)

Educational reference only — not medical advice.

Reported Benefits

Accelerated soft-tissue recovery in preclinical models
Gut barrier integrity and ulcer protection
Potential nervous system neuroprotection

Side Effects

Generally well tolerated in animal studies
Injection site irritation
Long-term human safety unknown

Contraindications

Active malignancy (theoretical angiogenic concern)
Pregnancy and lactation

Known Interactions

AnticoagulantsTheoretical synergy via NO modulation — monitor.

VEGF inhibitorsMechanistic opposition; avoid combination.

References

[1]Stable gastric pentadecapeptide BPC 157 — Current Pharmaceutical Design, 2018

Comparison vs Alternatives

All Peptides →

Attribute	BPC-157This page	TB-500	Semaglutide
Evidence	Grade B	Grade B	Grade A
Category	Regenerative	Regenerative	Metabolic
Best for	Tissue repair, gut integrity	Soft tissue regeneration	GLP-1 receptor agonist
Typical dose	250–500 mcg	2–5 mg	0.25 → 2.4 mg
Frequency	1–2× daily	2× per week loading (4 weeks), then 2–5 mg weekly maintenance	Weekly
Route	Subcutaneous or oral (gut-localized)	Subcutaneous or intramuscular injection	Subcutaneous weekly (oral form available)
Legal status	Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions.	WADA-prohibited at all times (S2 class). Research chemical; not approved for human therapeutic use.	FDA-approved (Ozempic, Wegovy). Prescription required.
Action	Current page	View →	View →

Related Peptides

MitochondrialGrade B